Ascendis Pharma A/S (NASDAQ:ASND) Given New $352.00 Price Target at TD Cowen

Key Points

• TD Cowen raised its price target on Ascendis Pharma to $352 from $341 and maintained a Buy rating, implying 31.23% upside from the prior close.
• Analyst sentiment is broadly positive: 19 analysts rate the stock Buy and two rate it Hold, with a consensus price target of $307.10.
• In its latest reported quarter, Ascendis missed EPS expectations ($1.03 versus $1.71) but exceeded revenue estimates, reporting $387.22 million.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price lifted by stock analysts at TD Cowen from $341.00 to $352.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. TD Cowen's price objective points to a potential upside of 31.23% from the company's previous close.

A number of other equities analysts have also issued reports on ASND. Jefferies Financial Group decreased their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a "buy" rating for the company in a research report on Monday, August 31st. Wedbush restated an "outperform" rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Thursday, October 15th. They set a "buy" rating and a $269.00 price target on the stock. HC Wainwright reduced their price target on shares of Ascendis Pharma A/S from $344.00 to $335.00 and set a "buy" rating for the company in a research note on Friday. Finally, Royal Bank Of Canada increased their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an "outperform" rating in a report on Friday, August 14th. Nineteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $307.10.

Ascendis Pharma A/S Stock Up 3.5%

ASND opened at $268.24 on Friday. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The stock has a market cap of $16.73 billion, a P/E ratio of 20.73 and a beta of 0.40. The stock's 50 day moving average price is $242.58 and its 200 day moving average price is $239.65.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, research analysts predict that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company's stock, valued at approximately $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 40.00% of the company's stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds have recently made changes to their positions in the business. First Trust Advisors LP boosted its holdings in Ascendis Pharma A/S by 435.8% during the third quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company's stock worth $19,807,000 after buying an additional 70,714 shares in the last quarter. Allianz SE increased its holdings in shares of Ascendis Pharma A/S by 219.4% in the third quarter. Allianz SE now owns 16,215 shares of the biotechnology company's stock valued at $3,694,000 after buying an additional 11,138 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at $6,075,000. GW&K Investment Management LLC increased its holdings in shares of Ascendis Pharma A/S by 121.2% in the third quarter. GW&K Investment Management LLC now owns 564 shares of the biotechnology company's stock valued at $128,000 after buying an additional 309 shares in the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Ascendis Pharma A/S by 21.0% during the 3rd quarter. USS Investment Management Ltd now owns 170,587 shares of the biotechnology company's stock valued at $38,878,000 after acquiring an additional 29,577 shares during the last quarter.

Key Ascendis Pharma A/S News

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.